Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal,
immunologically mediated adverse drug reaction to unfractionated heparin or, less …

Background: Extracorporeal membrane oxygenation (ECMO) offers therapeutic options in
refractory respiratory and/or cardiac failure. Systemic anticoagulation with heparin is …

We describe the first Danish case of presumed inflammatory and thrombotic response to
vaccination with an adenoviral (ChAdOx1) vector‐based COVID‐19 vaccine (AZD1222) …

This chapter about the recognition, treatment, and prevention of heparin-induced
thrombocytopenia (HIT) is part of the Antithrombotic and Thrombolytic Therapy: American …

Aims The clinical manifestation and outcomes of thrombosis with thrombocytopenia
syndrome (TTS) after adenoviral COVID-19 vaccine administration are largely unknown due …

Background: Many laboratories test for heparin‐induced thrombocytopenia (HIT) using a
PF4‐dependent enzyme‐immunoassay (EIA). An advantage of the EIA is its simplicity; a …

Immunoassays are essential in the workup of patients with suspected heparin-induced
thrombocytopenia. However, the diagnostic accuracy is uncertain with regard to different …

Background Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare
complication of adenoviral vector–based vaccines against SARS-CoV-2. This syndrome is …

Heparin-induced thrombocytopenia (HIT) is a prothrombotic drug reaction caused by platelet-
activating IgG antibodies that recognize platelet factor 4 (PF4)/polyanion complexes. Platelet …

Background Diagnosing heparin-induced thrombocytopenia (HIT) at the bedside remains
challenging, exposing a significant number of patients at risk of delayed diagnosis or …